Business Wire

CA-ANOMALI

11.11.2022 00:02:39 CET | Business Wire | Press release

Share
Anomali Appoints Udit Tibrewal as Chief Financial Officer and Chief Operating Officer

Anomali, the leader in modernizing and scaling security operations by delivering breakthrough levels of visibility and intelligence-driven threat detection and response, today announced that Udit Tibrewal has been appointed to the position of Chief Financial Officer (CFO) and Chief Operating Officer (COO). As Anomali’s CFO and COO, Tibrewal will report directly to Anomali’s CEO, Ahmed Rubaie, leading the company’s global business operations.

“Udit brings decades of experience to Anomali – both in cybersecurity and in building and scaling growth globally. His experience and expertise spanning finance, capital markets, and leading growth-stage companies to an initial public offering will be a tremendous asset to our customers, partners, and investors,” said Ahmed Rubaie, CEO. “Udit’s extensive leadership has been instrumental in helping organizations operate successfully and with the inception of the COO role, we further augment our leadership team and enter 2023 with a higher velocity operating model to help Anomali succeed.”

Tibrewal has more than 25 years of financial leadership and is recognized for his ability to build, scale, and create value. Most recently, Tibrewal was CFO for Arkose Labs, where he was appointed to the firm’s Executive Leadership Team. While at Arkose Labs, he was accountable for all aspects of the company’s global financial operations and led employee engagement, HR and recruiting, and legal and compliance. Recognized for his expertise guiding publicly traded, venture capital-backed and private equity-backed technology companies, he has helped global organizations achieve their strategic objectives. His tenure includes CFO at security and identity company SecureAuth, and SVP Finance of Sitecore, the global leader of context marketing management software. At Sitecore, he was instrumental in the $1.2 billion sale of the company. Additionally, he led the finance organization of ServiceSource, guiding the leading B2B technology platform company to an initial public offering and secondary offering. Tibrewal began his career in public accounting with Big Four firm, PwC.

“I am excited to join the Anomali team as the CFO and newly created role of COO and contribute to the mission of helping organizations modernize their security operations to stop breaches and advanced adversaries,” said Tibrewal. “I look forward to bringing my experience in the security domain and in leading growth stage companies to help Anomali build on its success, drive operational improvements across the company and execute its growth plan.”

For more information, visit: www.anomali.com

Twitter: https://twitter.com/Anomali
LinkedIn: https://www.linkedin.com/company/anomali/
Blog: https://www.anomali.com/blog

About Anomali

Anomali is the leader in modernizing and scaling security operations, delivering breakthrough levels of security visibility and intelligence-driven threat detection & response. In a world filled with SIEM, SOAR, XDR, the Anomali Platform amplifies visibility, integrating with existing security controls, and enriching them with actionable context to stop the adversaries. Anomali helps customers and partners transform their SOC platform by elevating security efficacy and reducing their cost with automated processes at the heart of everything. The solution is anchored in big-data management and boasts the world’s largest repository of global intelligence that supports native-cloud, multi-cloud, on-premises, and hybrid deployments. Founded in 2013, Anomali serves global B2B enterprise businesses, large public sector organizations, ISACs, ISAOs, service providers, and Global 1000 customers to help safeguard the world’s critical infrastructure, companies, and people. Leading venture firms, including Google Ventures, General Catalyst, and IVP, back Anomali. Learn more at www.anomali.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221110006102/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye